Nebenwirkungen · Litak
LITAK 2 mg/ml solution for injection · Abschnitt 4.8 · PDF-Seite 6
HOS-112293 · Präparat HOS-093643
Summary of the safety profile Very common adverse reactions observed during the three most relevant clinical trials with cladribine in 279 patients treated for various indications and in 62 patients with hairy cell leukaemia (HCL) were myelosuppression, especially severe neutropenia (41% (113/279), HCL 98% (61/62)), severe thrombocytopenia (21% (58/279), HCL 50% (31/62)) and severe anaemia (14% (21/150), HCL 55% (34/62)), as well as severe immunosuppression/lymphopenia (63% (176/279), HCL 95% (59/62)), infections (39% (110/279), HCL 58% (36/62)) and fever (up to 64%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-03T02:00:00Z · SHA-256 42ba8788ffbc14f662af334f85de7bff88a9741607012fc723ea0ee7baaee9b6 · Passage 8e3759d60bae5d770c15b7fa98b8c9611ef665c4f65ec32e80bb25d3031dc226 · Zeichen 0–574 im Abschnitt